Filing Flows › RxSight (RXST) › R&D spending
RxSight (RXST) R&D spending by quarter
RxSight's R&D spending was $9.2M in Q3 2026 (third quarter 2026), -0.3% from Q2 2026. Over the last 7 quarters it ranged from $8.9M (Q4 2025) to $10.4M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $9.2M | -0.3% | +2% |
| Q2 2026 | $9.2M | -2% | -10% |
| Q1 2026 | $9.5M | +6% | -9% |
| Q4 2025 | $8.9M | -2% | — |
| Q3 2025 | $9.1M | -11% | — |
| Q2 2025 | $10.2M | -1% | — |
| Q1 2025 | $10.4M | — | — |
Q3 2026 at a glance
RxSight, Q3 2026: revenue $24.6M (-19% year over year), operating margin -75.3%, net loss $16.2M, operating cash flow $45.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is RxSight's R&D spending?
RxSight's R&D spending was $9.2M in Q3 2026 (third quarter 2026), -0.3% from Q2 2026.
How has RxSight's R&D spending changed?
Over the last 7 quarters it ranged from $8.9M (Q4 2025) to $10.4M (Q1 2025).